tirzepatide heart health Can tirzepatide, a long-acting agonist of glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 receptors, provide effective treatment for patients with failure and a preserved ejection fraction who also have obesity? β£ β£ ππ©ππππ π’π§ πππ«ππ’π¨π¦πππππ¨π₯π’π πππ«π A
Description
In the SURMOUNT-1 trial, also published in NEJM, participants receiving tirzepatide achieved weight reductions ranging from 16.0% to 22.5% depending on dose over 72 weeks
Proton-pump inhibitor-induced hypomagnesemia: Current research and proposed mechanisms
Here, a weekend guide on where to stay and where to eat when visiting The Scenic City
How Tadalafil Works for Erectile Dysfunction Tadalafil does not create an automatic erection
GLP-1 drugs can reduce total body fat, but the seen shape might not significantly shift
